Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 07 07 2020
revised: 02 12 2020
accepted: 21 01 2021
pubmed: 5 3 2021
medline: 15 4 2021
entrez: 4 3 2021
Statut: ppublish

Résumé

Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3 at the nexus of a translation-based program that rewires splicing during malignant transformation. Upon MYC hyperactivation, SF3A3 levels are modulated translationally through an RNA stem-loop in an eIF3D-dependent manner. This ensures accurate splicing of mRNAs enriched for mitochondrial regulators. Altered SF3A3 translation leads to metabolic reprogramming and stem-like properties that fuel MYC tumorigenic potential in vivo. Our analysis reveals that SF3A3 protein levels predict molecular and phenotypic features of aggressive human breast cancers. These findings unveil a post-transcriptional interplay between splicing and translation that governs critical facets of MYC-driven oncogenesis.

Identifiants

pubmed: 33662273
pii: S1097-2765(21)00054-X
doi: 10.1016/j.molcel.2021.01.034
pii:
doi:

Substances chimiques

MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
RNA Splicing Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1453-1468.e12

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.B. received travel grants from Roche and participated in advisory board meetings for Pfizer and Novartis. All other authors declare no competing interests.

Auteurs

Maciej Cieśla (M)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Phuong Cao Thi Ngoc (PCT)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Eugenia Cordero (E)

Division of Translational Cancer Research, Department of Laboratory Medicine, Faculty of Medicine, Lund University, 22363 Lund, Sweden.

Álvaro Sejas Martinez (ÁS)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Mikkel Morsing (M)

Division of Translational Cancer Research, Department of Laboratory Medicine, Faculty of Medicine, Lund University, 22363 Lund, Sweden.

Sowndarya Muthukumar (S)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Giulia Beneventi (G)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Magdalena Madej (M)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Roberto Munita (R)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Terese Jönsson (T)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden.

Kristina Lövgren (K)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Anna Ebbesson (A)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Björn Nodin (B)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Ingrid Hedenfalk (I)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Karin Jirström (K)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Johan Vallon-Christersson (J)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Gabriella Honeth (G)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Johan Staaf (J)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Danny Incarnato (D)

Faculty of Science and Engineering, University of Groningen, Groningen, the Netherlands.

Kristian Pietras (K)

Division of Translational Cancer Research, Department of Laboratory Medicine, Faculty of Medicine, Lund University, 22363 Lund, Sweden.

Ana Bosch (A)

Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. Electronic address: ana.bosch_campos@med.lu.se.

Cristian Bellodi (C)

Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, 22184 Lund, Sweden. Electronic address: cristian.bellodi@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH